Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
CONCLUSIONS: Occurrence of FS is low in patients with HIV treated with tenofovir-based regimens. Concomitant use of ritonavir may increase risk of FS. TAF may be a safer alternative than TDF in terms of nephrotoxicity.PMID:37932920 | DOI:10.1177/10600280231206703 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 7, 2023 Category: Drugs & Pharmacology Authors: Mrinmayee Joshi Brendan Clark Todd A Lee Source Type: research
Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
CONCLUSIONS: Occurrence of FS is low in patients with HIV treated with tenofovir-based regimens. Concomitant use of ritonavir may increase risk of FS. TAF may be a safer alternative than TDF in terms of nephrotoxicity.PMID:37932920 | DOI:10.1177/10600280231206703 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 7, 2023 Category: Drugs & Pharmacology Authors: Mrinmayee Joshi Brendan Clark Todd A Lee Source Type: research
Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
CONCLUSIONS: Occurrence of FS is low in patients with HIV treated with tenofovir-based regimens. Concomitant use of ritonavir may increase risk of FS. TAF may be a safer alternative than TDF in terms of nephrotoxicity.PMID:37932920 | DOI:10.1177/10600280231206703 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 7, 2023 Category: Drugs & Pharmacology Authors: Mrinmayee Joshi Brendan Clark Todd A Lee Source Type: research
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research
Zavegepant Intranasal Spray for Migraines
CONCLUSION: Zavegepant may be a convenient and useful acute treatment option for migraines with and without aura.PMID:37897226 | DOI:10.1177/10600280231209439 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Amber Lanae Martirosov Christopher Giuliano Macy Shupp Sarah Channey Pramodini B Kale-Pradhan Source Type: research
Real-World Experience With CMV inSIGHT T Cell Immunity Testing in High-Risk Kidney and Pancreas Transplant Recipients
CONCLUSION AND RELEVANCE: The data obtained from the TCIP are not static, immune control of CMV in latency can change and must be evaluated in clinical context. Timing of TCIP after transplant is significant, and patient-specific factors remain important to assess the likelihood of CMV in each unique patient-specific scenario. A CMV stewardship program can aid in application and interpretation of results.PMID:37897238 | DOI:10.1177/10600280231207899 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Jillian L Descourouez Jeannina A Smith Christopher M Saddler Didier A Mandelbrot Jon S Odorico Margaret R Jorgenson Source Type: research
Zavegepant Intranasal Spray for Migraines
CONCLUSION: Zavegepant may be a convenient and useful acute treatment option for migraines with and without aura.PMID:37897226 | DOI:10.1177/10600280231209439 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Amber Lanae Martirosov Christopher Giuliano Macy Shupp Sarah Channey Pramodini B Kale-Pradhan Source Type: research
Real-World Experience With CMV inSIGHT T Cell Immunity Testing in High-Risk Kidney and Pancreas Transplant Recipients
CONCLUSION AND RELEVANCE: The data obtained from the TCIP are not static, immune control of CMV in latency can change and must be evaluated in clinical context. Timing of TCIP after transplant is significant, and patient-specific factors remain important to assess the likelihood of CMV in each unique patient-specific scenario. A CMV stewardship program can aid in application and interpretation of results.PMID:37897238 | DOI:10.1177/10600280231207899 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Jillian L Descourouez Jeannina A Smith Christopher M Saddler Didier A Mandelbrot Jon S Odorico Margaret R Jorgenson Source Type: research
Zavegepant Intranasal Spray for Migraines
CONCLUSION: Zavegepant may be a convenient and useful acute treatment option for migraines with and without aura.PMID:37897226 | DOI:10.1177/10600280231209439 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Amber Lanae Martirosov Christopher Giuliano Macy Shupp Sarah Channey Pramodini B Kale-Pradhan Source Type: research
LCP-Tacrolimus Requires a Similar Empiric Dose Adjustment to Immediate-Release Tacrolimus When Given Concomitantly With Letermovir for Cytomegalovirus Primary Prophylaxis
Ann Pharmacother. 2023 Oct 27:10600280231208430. doi: 10.1177/10600280231208430. Online ahead of print.NO ABSTRACTPMID:37887433 | DOI:10.1177/10600280231208430 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 27, 2023 Category: Drugs & Pharmacology Authors: Jillian L Descourouez Didier A Mandelbrot Jon Odorico Margaret R Jorgenson Source Type: research
